Minang Pravin Turakhia, MD
Cardiac Electrophysiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Turakhia’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A83028 · Current
Licensed to practise in California · since 2003 · expires 2027-02-28 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Medicaid work
$109 in 2020
Medicaid paid $109 for 15 billed services this clinician did in 2020, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 15 | $109 |
| 2020 | 15 | 1 | 15 | $109 |
| 2019 | 50 | 1 | 47 | $474 |
| 2018 | 140 | 1 | 55 | $1,263 |
See the largest Medicaid services in earlier years
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 50 | $474 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 140 | $1,263 |
Money from drug and device companies
$60 in 2025
| 2025 | 2 | 2 | None | $60 |
| 2024 | 1 | 1 | None | $84 |
| 2023 | 1 | 2 | $4,500 | $4,500 |
| 2022 | 5 | 10 | $11,068 | $11,171 |
| 2021 | 6 | 29 | $32,230 | $35,526 |
| 2020 | 7 | 13 | $23,703 | $24,181 |
| 2019 | 12 | 53 | $25,771 | $34,960 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Medtronic | Meals · 2025-09-05 | Micra | $35 |
| AtriCure | Meals · 2025-06-03 | Atricure Cryoice Cryoablation System (Cryo2) | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $84
| Edwards Lifesciences | None | $84 | 1 payment
|
2023: $4,500
| Sanofi-Aventis U.S. | Multaq | $4,500 | 2 payments
|
2022: $11,171
| Sanofi-Aventis U.S. | Multaq | $5,868 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $3,400 | 1 payment
|
| Medtronic | Linq II | $1,224 | 2 payments
|
| Abbott Laboratories | Ensite Precision | $600 | 1 payment
|
| Biotronik | Edora 8 Dr-T | $79 | 1 payment
|
2021: $35,526
| E.R. Squibb & Sons L.L.C. | Eliquis | $12,000 | 2 payments
|
| Medtronic | Linq II | $9,677 | 21 payments
|
| Pfizer | Eliquis | $8,500 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Non-Covered | $3,330 | 1 payment
|
| Abbott Laboratories | Cardiomems Hf System | $1,219 | 2 payments
|
| Biotronik | Solia | $800 | 1 payment
|
2020: $24,181
| Sanofi-Aventis U.S. | Multaq | $7,828 | 2 payments
|
| Medtronic Vascular | None | $7,300 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $4,138 | 2 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $2,719 | 3 payments
|
| Biotronik | None | $1,638 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $537 | 1 payment
|
| Cardiva Medical | Vascular Closure Device | $22 | 1 payment
|
2019: $34,960
| Novartis Pharmaceuticals | Entresto | $13,888 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $6,500 | 2 payments
|
| Pfizer | Eliquis | $3,085 | 7 payments
|
| Bayer HealthCare Pharmaceuticals | None | $3,000 | 1 payment
|
| Medtronic Vascular | Micra | $2,825 | 14 payments
|
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $2,144 | 4 payments
|
| Biotronik | None | $1,746 | 2 payments
|
| Medical Device Business Services | None | $765 | 1 payment
|
| Janssen Research & Development | None | $666 | 5 payments
|
| Boston Scientific | General Ep | $214 | 6 payments
|
| Biosense Webster | None | $77 | 1 payment
|
| Janssen Scientific Affairs | Xarelto | $50 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · Reducing Noac Dose-Patient Mismatch · 2022 | Their institution | $20,804 |
| Medtronic Vascular, Inc. · Bluesync · 2020 | Their institution | $11,875 |
| Janssen Scientific Affairs, LLC · Heartline Research Study · 2020 | Their institution | $11,850 |
| Medtronic Vascular, Inc. · Define Afib · 2020 | Their institution | $9,150 |
| Medtronic Vascular, Inc. · Bluesync · 2019 | Their institution | $8,065 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Gloria Af Registry Phase II III Core · 2019 | Their institution | $5,239 |
| Medtronic, Inc. · Define Afib · 2022 | Their institution | $3,450 |
| E.R. Squibb & Sons, L.L.C. · Observational Data To Address Major Evidence Gaps for Noacs in Af · 2022 | Their institution | $2,300 |
| Janssen Scientific Affairs, LLC · Heartline Research Study · 2022 | Their institution | $2,100 |
| SANOFI-AVENTIS U.S. LLC · Impact of Dronedarone on Cv Hospitalization, Mortality, and Proarrhythmia in Af Patients Based on the Optumc Clinformaticst Data Mart and Ibm Marketscan Representative of the Entire Ins · 2025 | This clinician | $1,250 |
| SANOFI-AVENTIS U.S. LLC · Impact of Dronedarone on Cv Hospitalization and Ventricular Proarrhythmia in Af Patients Based on the Optum Clinformatics Data Mart, Ibm Marketscan, Veterans Health Administration Electronic Health Records, and Swedish National Patient Register Databases Representative of the Entire Insured US and Swedish Populations · 2023 | This clinician | $1,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Gloria Af Registry Phase II III Core · 2020 | Their institution | $791 |
| Medtronic, Inc. · Define Afib · 2021 | Their institution | $250 |
Professional record
- NPI
- 1528114204
- Licence
- CA A83028California A83028: Current · expires 2027-02-28
- Trained
- University of California, San Francisco School of Medicine, 2000
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-26
- NPI last updated
- 2025-07-22
- NPI record certified
- 2025-07-22
This is when the NPI record was last certified, not a medical board exam.